Assessment of What Patients and Healthcare Providers Value

"What Do You Value?" A Survey Study Assessing How Patients and Health Care Providers Weigh the Different Components of the Value Equation

To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience), and how these patients’ views differ depending on the stage of their therapy (pretreatment, preoperative therapy, post-operative, long-term surveillance, recurrence).

Study Overview

• Status: Completed
• Conditions: Pancreatic Adenocarcinoma; Gastric Adenocarcinoma; Pancreatic Neuroendocrine Carcinoma
• Intervention / Treatment: Other: Survey Administration

Detailed Description

PRIMARY OBJECTIVE:

I. To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience).

SECONDARY OBJECTIVES:

I. To assess which attributes of value (i.e., outcomes, QOL, cost, experience) health care providers (i.e., physicians, nurses, administrators) feel are most important in health care delivery.

II. To assess how these patients' views differ depending on the stage of their therapy (pretreatment, preoperative therapy, post-operative, long-term surveillance, recurrence).

III. To assess how patients' view differ to health providers.

OUTLINE:

Patients and healthcare providers complete a survey over 10-15 minutes.

• Study Type: Observational
• Enrollment (Actual): 397

Contacts and Locations

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • M D Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with pancreatic adenocarcinoma, pancreatic neuroendocrine malignancy, or gastric adenocarcinoma, and healthcare providers involved in the care of gastric and pancreatic cancer patients at the MD Anderson Cancer Center

Description

Inclusion Criteria:

• Any patient who has been treated, or is anticipated to be treated, for potentially resectable, biopsy-proven pancreatic adenocarcinoma, pancreatic neuroendocrine malignancy, or gastric adenocarcinoma
• Providers involved in the care of gastric and pancreatic cancer patients. Providers will include non-collaborative surgical oncologists, medical oncologists, radiation oncologists, administrators, nurses, mid-level providers
• Able to understand the description of the study and willing to participate

Exclusion Criteria:

• Inability to read and answer questions in English

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Observational (survey administration); Patients and healthcare providers complete a survey over 10-15 minutes.	Other: Survey Administration; Complete survey

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Importance patients place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)	We will calculate the mean rank of patients yielding usable data and its corresponding 95% confidence interval. Patient characteristics and survey items will be summarized using descriptive statistics, including means, standard deviations (SDs), proportions, range, and 95% confidence intervals (CIs), etc.	Survey completion up to 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Most important attributes of value to healthcare providers	Provider characteristics and survey items will be summarized using descriptive statistics, including means, SDs, proportions, range, and 95% CIs, etc.	Survey completion up to 1 year
Importance care providers (i.e., physicians, nurses, administrators) place on each of the attributes of value (i.e., outcomes, quality of life [QOL], cost, experience)	Chi-square tests (or Fisher's exact test) will be used to compare the results between patients and providers.	Survey completion up to 1 year

Collaborators and Investigators

• Sponsor: M.D. Anderson Cancer Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Matthew H Katz, M.D. Anderson Cancer Center

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): June 11, 2020
• Primary Completion (Actual): August 11, 2022
• Study Completion (Actual): August 11, 2022

Study Registration Dates

• First Submitted: July 14, 2020
• First Submitted That Met QC Criteria: July 21, 2020
• First Posted (Actual): July 23, 2020

Study Record Updates

• Last Update Posted (Actual): August 31, 2022
• Last Update Submitted That Met QC Criteria: August 30, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Endocrine System Diseases; Digestive System Neoplasms; Endocrine Gland Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Pancreatic Diseases; Neuroendocrine Tumors; Pancreatic Neoplasms; Adenocarcinoma; Carcinoma, Neuroendocrine; Carcinoma, Islet Cell
• Other Study ID Numbers: 2020-0211 (Other Identifier: M D Anderson Cancer Center); P30CA016672 (U.S. NIH Grant/Contract); NCI-2020-04577 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No